Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332514 · ClinicalTrials.gov registry record · Phase 2
Post-Discharge Follow-Up Phone Call by a Pharmacist and Impact on Patient Care
A Phase 2 study of Readmission, Hospital, sponsored by Boston Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00332514: Completed Phase 2 study of Readmission, Hospital, sponsored by Boston Medical Center.
NCT00332514 is a Phase 2 study of Readmission, Hospital that has completed, run by Boston Medical Center. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00332514, a Phase 2 study of Readmission, Hospital, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose is to analyze whether a follow-up telephone call by a pharmacist after patient discharge from the hospital can improve patient outcomes. Patients will be interviewed via telephone within 72 hours of being discharged home from the hospital. Patients will be questioned on three main topics. They are: 1. Medical care 2. Medications 3. Follow-up appointments The purpose is to find out if people understand discharge medications, have obtained those medications, are having any problems with their medications and have scheduled necessary follow-up appointments. It will be determined if a telephone call by a pharmacist will prevent patients from needing to go to the Emergency Room or being admitted back to the hospital.
Conditions Studied
Interventions
- BEHAVIORAL telephone call by a pharmacist
Study Locations (1)
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2004-03 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
What the finished NCT00332514 record still lists
NCT00332514 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Readmission, Hospital appearing as the primary indexed condition, and to 1 intervention - of which telephone call by a pharmacist is the first listed.
NCT00332514 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00332514 about?
NCT00332514 is a clinical study titled "Post-Discharge Follow-Up Phone Call by a Pharmacist and Impact on Patient Care". The purpose is to analyze whether a follow-up telephone call by a pharmacist after patient discharge from the hospital can improve patient outcomes. Patients will be interviewed via telephone within 72 hours of being discharged home from the hospital. Patients will be questioned on three main topic...
What is the current status of trial NCT00332514?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2004-03. Estimated completion is 2008-01.
What conditions does trial NCT00332514 study?
This clinical trial studies the following conditions: Readmission, Hospital.
What interventions are being tested in trial NCT00332514?
The interventions under investigation include: telephone call by a pharmacist (BEHAVIORAL).
Who is sponsoring clinical trial NCT00332514?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00332514 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Readmission, Hospital
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00332514's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia